De Placido S - Search Results

1

Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.

Formisano L, D'Amato V, Servetto A, Brillante S, Raimondo L, Di Mauro C, Marciano R, Orsini RC, Cosconati S, Randazzo A, Parsons SJ, Montuori N, Veneziani BM, De Placido S, Rosa R, Bianco R. Formisano L, et al. Among authors: de placido s. Oncotarget. 2015 Sep 22;6(28):26090-103. doi: 10.18632/oncotarget.4636. Oncotarget. 2015. PMID: 26325669 Free PMC article.

2

Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.

Tortora G, Caputo R, Damiano V, Caputo R, Troiani T, Veneziani BM, De Placido S, Bianco AR, Zangemeister-Wittke U, Ciardiello F. Tortora G, et al. Among authors: de placido s. Clin Cancer Res. 2003 Feb;9(2):866-71. Clin Cancer Res. 2003. PMID: 12576461

3

Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.

Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F. Tortora G, et al. Among authors: de placido s. Clin Cancer Res. 2003 Apr;9(4):1566-72. Clin Cancer Res. 2003. PMID: 12684433

4

Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease.

Di Lorenzo G, Autorino R, De Laurentiis M, Bianco R, Lauria R, Giordano A, De Sio M, D'Armiento M, Bianco AR, De Placido S. Di Lorenzo G, et al. Among authors: de placido s, de sio m, de laurentiis m. Tumori. 2003 Jul-Aug;89(4):349-60. doi: 10.1177/030089160308900402. Tumori. 2003. PMID: 14606635 Review.

5

Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, Tortora G. Ciardiello F, et al. Among authors: de placido s, de vita f. Clin Cancer Res. 2004 Jan 15;10(2):784-93. doi: 10.1158/1078-0432.ccr-1100-03. Clin Cancer Res. 2004. PMID: 14760102

6

Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.

Bianco R, Caputo R, Caputo R, Damiano V, De Placido S, Ficorella C, Agrawal S, Bianco AR, Ciardiello F, Tortora G. Bianco R, et al. Among authors: de placido s. Clin Cancer Res. 2004 Jul 15;10(14):4858-64. doi: 10.1158/1078-0432.CCR-03-0497. Clin Cancer Res. 2004. PMID: 15269162

7

Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma.

Damiano V, Melisi D, Bianco C, Raben D, Caputo R, Fontanini G, Bianco R, Ryan A, Bianco AR, De Placido S, Ciardiello F, Tortora G. Damiano V, et al. Among authors: de placido s. Clin Cancer Res. 2005 Aug 1;11(15):5639-44. doi: 10.1158/1078-0432.CCR-05-0174. Clin Cancer Res. 2005. PMID: 16061883

8

Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer.

Melisi D, Caputo R, Damiano V, Bianco R, Veneziani BM, Bianco AR, De Placido S, Ciardiello F, Tortora G. Melisi D, et al. Among authors: de placido s. Endocr Relat Cancer. 2005 Dec;12(4):1051-8. doi: 10.1677/erc.1.01061. Endocr Relat Cancer. 2005. PMID: 16322342

9

Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.

Damiano V, Caputo R, Bianco R, D'Armiento FP, Leonardi A, De Placido S, Bianco AR, Agrawal S, Ciardiello F, Tortora G. Damiano V, et al. Among authors: de placido s. Clin Cancer Res. 2006 Jan 15;12(2):577-83. doi: 10.1158/1078-0432.CCR-05-1943. Clin Cancer Res. 2006. PMID: 16428503

10

TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts.

Damiano V, Caputo R, Garofalo S, Bianco R, Rosa R, Merola G, Gelardi T, Racioppi L, Fontanini G, De Placido S, Kandimalla ER, Agrawal S, Ciardiello F, Tortora G. Damiano V, et al. Among authors: de placido s. Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12468-73. doi: 10.1073/pnas.0705226104. Epub 2007 Jul 16. Proc Natl Acad Sci U S A. 2007. PMID: 17636117 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

398 results

Search Page

Filters